BeyondAirInc . (NASDAQ: XAIR) is one of 127 public companies in the “Surgical & medical instruments” industry, but how does it weigh in compared to its competitors? We will compare BeyondAirInc . to similar businesses based on the strength of its earnings, risk, analyst recommendations, dividends, institutional ownership, profitability and valuation.
This table compares BeyondAirInc . and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|BeyondAirInc . Competitors||-674.05%||-624.58%||-22.23%|
This is a breakdown of recent ratings and recommmendations for BeyondAirInc . and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|BeyondAirInc . Competitors||933||3162||5359||281||2.51|
As a group, “Surgical & medical instruments” companies have a potential upside of 19.14%. Given BeyondAirInc .’s competitors higher possible upside, analysts clearly believe BeyondAirInc . has less favorable growth aspects than its competitors.
Valuation and Earnings
This table compares BeyondAirInc . and its competitors top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|BeyondAirInc .||$7.72 million||-$6.56 million||-5.92|
|BeyondAirInc . Competitors||$1.43 billion||$145.31 million||-12.15|
BeyondAirInc .’s competitors have higher revenue and earnings than BeyondAirInc .. BeyondAirInc . is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Insider & Institutional Ownership
0.3% of BeyondAirInc . shares are held by institutional investors. Comparatively, 51.1% of shares of all “Surgical & medical instruments” companies are held by institutional investors. 15.2% of shares of all “Surgical & medical instruments” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Risk and Volatility
BeyondAirInc . has a beta of -0.27, suggesting that its stock price is 127% less volatile than the S&P 500. Comparatively, BeyondAirInc .’s competitors have a beta of 1.00, suggesting that their average stock price is 0% less volatile than the S&P 500.
BeyondAirInc . competitors beat BeyondAirInc . on 7 of the 10 factors compared.
BeyondAirInc . Company Profile
Beyond Air, Inc., a clinical-stage medical device and biopharmaceutical company, develops nitric oxide (NO) delivery systems to treat respiratory tract infections and other diseases. Its NO delivery systems are used for the treatment of pulmonary hypertension of the newborn, bronchiolitis, and nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. The company is based in Garden City, New York.
Receive News & Ratings for BeyondAirInc . Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondAirInc . and related companies with MarketBeat.com's FREE daily email newsletter.